Почетна › Akutna mijeloidna leukemija › Орегон
Kliničke studije za Akutna mijeloidna leukemija u državi Орегон
26 studija za Akutna mijeloidna leukemija traži učesnike na lokacijama u državi Орегон.
Gradovi u državi Орегон
Zvanični tekst studije (na engleskom)
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Providence Newberg Medical Center, Newberg
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Willamette Falls Medical Center, Oregon City
- и још 2
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06317649Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- Willamette Valley Cancer Institute, Eugene
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT07007312Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
Тражи се учесникФаза 2
Узраст од 18 до 59 · Оба пола · Ажурирано 9. 11. 2026. · NCT05554406Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Saint Alphonsus Cancer Care Center-Baker City, Baker City
- Saint Charles Health System, Bend
- Clackamas Radiation Oncology Center, Clackamas
- и још 7
Тражи се учесникОпсервациона студијаЗдраве особе су добродошле
Узраст од 40 до 75 · Оба пола · Ажурирано 4. 11. 2026. · NCT05334069A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Providence Portland Medical Center, Portland
- Providence Oncology and Hematology Care Clinic Westside, Portland
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT06852222MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Providence Newberg Medical Center, Newberg
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Willamette Falls Medical Center, Oregon City
- и још 2
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 2. 11. 2026. · NCT05564390Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
- Oregon Health & Science University (OHSU) - Knight Cancer Institute, Portland
Тражи се учесникФаза 3
Узраст од 18 до 75 · Оба пола · Ажурирано 30. 10. 2026. · NCT05429632Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Saint Alphonsus Cancer Care Center-Ontario, Ontario
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
Тражи се учесникФаза 2
Узраст од 18 до 59 · Оба пола · Ажурирано 28. 10. 2026. · NCT05554393Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia
- OHSU Knight Cancer Institute, Portland
Тражи се учесникФаза 2
Узраст од 18 до 65 · Оба пола · Ажурирано 20. 10. 2026. · NCT07228273A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- Oregon Health & Science University, Portland
Тражи се учесникФаза 1/2
30 Days · Оба пола · Ажурирано 9. 10. 2026. · NCT04065399A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Oregon Health and Science University, Portland
- Oregon Oncology Specialists, Salem
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 6. 10. 2026. · NCT04256317Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation
- OHSU Knight Cancer Institute, Portland
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 5. 10. 2026. · NCT07548983Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- OHSU Knight Cancer Institute, Portland
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 24. 9. 2026. · NCT03874052A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Legacy Emanuel Children's Hospital, Portland
- Oregon Health and Science University, Portland
Тражи се учесникФаза 3
6 Months – 21 Years · Оба пола · Ажурирано 17. 9. 2026. · NCT04293562Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML
- OHSU Knight Cancer Institute, Portland
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 16. 9. 2026. · NCT06504459Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- Oregon Health and Science University, Portland
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 14. 9. 2026. · NCT03471260Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
- US-Portland OR-OHSU, Portland
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 2. 9. 2026. · NCT06652438The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Legacy Emanuel Children's Hospital, Portland
- Oregon Health and Science University, Portland
Тражи се учесникФаза 1/2
До 22 година · Оба пола · Ажурирано 25. 8. 2026. · NCT04726241Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
- OHSU Knight Cancer Institute, Portland
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 14. 7. 2026. · NCT04659616Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Oregon Health and Science University, Portland
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 7. 7. 2026. · NCT07216443A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Oregon Health & Science University/Doernbecher Children's Hospital, Portland
Тражи се учесникОпсервациона студија
Сви узрасти · Оба пола · Ажурирано 6. 7. 2026. · NCT01351545Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia
- OHSU Knight Cancer Institute, Portland
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 30. 6. 2026. · NCT06357182A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Oncology Associates of Oregon, Eugene
Тражи се учесникФаза 1/2
Узраст 12 и старији · Оба пола · Ажурирано 24. 3. 2026. · NCT04988555A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- Oregon Health & Science University, Portland
Тражи се учесникФаза 2
Узраст од 18 до 66 · Оба пола · Ажурирано 17. 3. 2026. · NCT06859424A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
- OHSU, Portland
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 9. 2. 2026. · NCT06950034Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
- Oregon Health & Science University, Portland
Тражи се учесникЗдраве особе су добродошле
Узраст од 18 до 120 · Оба пола · Ажурирано 25. 7. 2025. · NCT05237258Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.